Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported first quarter 2026 net product revenue of $6.9 million, a significant increase from $2.4 million in the same period in 2025. The revenue growth is primarily driven by the commercial launch of TONMYA, which generated $3.7 million in net sales. The company signed a managed care partnership with a leading group purchasing organization (GPO) in May, providing access to TONMYA for approximately 35 million U.S. commercial lives.
Key figures
- Eps Beat
- 0
- Revenue
- 6878000
- Revenue Yoy
- 183.3%
- Tonmya revenue
- 3700000
- Tonmya gpo coverage
- 35000000
- Tonmya net cash used
- 42300000
- Tonmya prescriptions
- 5400
- Tonmya unique patients
- 3588
- Tonmya unique providers
- 2145
- Tonmya medicaid coverage
- 55000000
- Zembrace tosymra revenue
- 3200000
- Tonmya shares outstanding
- 15940601
- Tonmya cumulative prescriptions
- 11016
- Tonmya cash and cash equivalents
- 185470000
- Tonmya cumulative unique patients
- 5618
- Tonmya cumulative unique providers
- 2700
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.